Bimekizumab Efficacy and Safety Through 3 Years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II Trials and Their Open-Label Extension BE HEARD EXT. (2026). SKIN The Journal of Cutaneous Medicine, 10(2), s762. https://doi.org/10.25251/g776yf41